| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T371 |
0-193 |
Sentence |
denotes |
Vidofludimus is a synthetic small molecule that is under investigation for treating inflammatory bowel disease, multiple sclerosis, and other inflammatory and autoimmune diseases [154,155,156]. |
| T372 |
194-320 |
Sentence |
denotes |
It is a biphenyl-carbamoyl-cyclopentene derivative (Figure 7) that is being developed as oral formulation for therapeutic use. |
| T373 |
321-553 |
Sentence |
denotes |
Currently, a prospective, randomized, multi-center, double-blinded, and placebo-controlled study is ongoing to evaluate the safety and efficacy of vidofludimus as an adjunct therapy in COVID-19 patients (NCT04379271; n = 230) [157]. |
